東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Engineered CAR-T Cells for Treatment...

Siriwon, Natnaree.

Linked to FindBook

Google Book

Amazon

博客來

Engineered CAR-T Cells for Treatment of Solid Cancers.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Engineered CAR-T Cells for Treatment of Solid Cancers./
Author:	Siriwon, Natnaree.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
Description:	106 p.
Notes:	Source: Dissertations Abstracts International, Volume: 80-08, Section: B.
Contained By:	Dissertations Abstracts International80-08B.
Subject:	Chemical engineering. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=11017006

Engineered CAR-T Cells for Treatment of Solid Cancers.
Siriwon, Natnaree.

Engineered CAR-T Cells for Treatment of Solid Cancers. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 106 p.

Source: Dissertations Abstracts International, Volume: 80-08, Section: B.

Thesis (Ph.D.)--University of Southern California, 2018.

This item must not be sold to any third party vendors.

The chimeric antigen receptor T (CAR-T) cell therapy has become a promising cancer immunotherapeutic method, particularly in treating B cell malignancies; however, this therapy is still in the early stages of development for the treatment of solid tumors. One limiting factor of CAR-T cell therapy is the suppressive tumor microenvironment, which inactivates the function of tumor infiltrating lymphocyte (TIL). This thesis work is divided into two major studies that aim to overcome two different immunosuppressive mechanisms in the TME: adenosine up-regulation and PD-1/PD-L1 immune inhibition. In the first study, we surface-engineered CAR-T cells to deliver an A2a receptor small molecule inhibitor in the TME. The small molecule inhibitor is encapsulated in cross- linked multilamellar liposomes, which are covalently conjugated to the surface of CAR-T cells. We hypothesized that this co-delivery strategy would be able to enhance CAR-T cell functions in the TME and, consequently, augment CAR-T cell antitumor activities. We demonstrated in this study that our drug delivery strategy was able to prevent CAR-T cells from becoming hypofunctional in the TME and improved CAR-T cell antitumor response. Moreover, we showed that the antitumor function of tumor infiltrated CAR-T cells could be rescued upon interference of the adenosine pathway using A2a receptor small molecule inhibitors. This study signifies the effects adenosine has on tumor infiltrating immune cells and demonstrated a strategy in which it could be overcome, in order to improve the efficacy of CAR-T cell therapy. The second obstacle we aim to overcome is the PD-1/PD-L1 immune regulatory pathway. In the second study, we engineered CAR-T cells to secrete the PD-1/PD-L1 checkpoint inhibitor and evaluated the antitumor efficacy in vivo. This strategy was proved to significantly enhance CAR-T cell effector functions in vivo and was able to completely eradicate established tumors. We evaluated the effector functions in an ex vivo assay and demonstrated that the intrinsically secreted PD-1/PD-L1 checkpoint inhibitor was able to prevent CAR-T cell exhaustion and maintained IFN? secretion upon restimulation.Subjects--Topical Terms:

560457
Chemical engineering.

Engineered CAR-T Cells for Treatment of Solid Cancers.
LDR:03190nmm a2200301 4500 001 2209300
005 20191104073136.5
008 201008s2018 ||||||||||||||||| ||eng d
035 $a (MiAaPQ)AAI11017006
035 $a (MiAaPQ)US_Calif_58781
035 $a AAI11017006
040 $a MiAaPQ $c MiAaPQ
100 1 $a Siriwon, Natnaree. $3 3436383
245 1 0 $a Engineered CAR-T Cells for Treatment of Solid Cancers.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 106 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-08, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Wang, Pin.
502 $a Thesis (Ph.D.)--University of Southern California, 2018.
506 $a This item must not be sold to any third party vendors.
520 $a The chimeric antigen receptor T (CAR-T) cell therapy has become a promising cancer immunotherapeutic method, particularly in treating B cell malignancies; however, this therapy is still in the early stages of development for the treatment of solid tumors. One limiting factor of CAR-T cell therapy is the suppressive tumor microenvironment, which inactivates the function of tumor infiltrating lymphocyte (TIL). This thesis work is divided into two major studies that aim to overcome two different immunosuppressive mechanisms in the TME: adenosine up-regulation and PD-1/PD-L1 immune inhibition. In the first study, we surface-engineered CAR-T cells to deliver an A2a receptor small molecule inhibitor in the TME. The small molecule inhibitor is encapsulated in cross- linked multilamellar liposomes, which are covalently conjugated to the surface of CAR-T cells. We hypothesized that this co-delivery strategy would be able to enhance CAR-T cell functions in the TME and, consequently, augment CAR-T cell antitumor activities. We demonstrated in this study that our drug delivery strategy was able to prevent CAR-T cells from becoming hypofunctional in the TME and improved CAR-T cell antitumor response. Moreover, we showed that the antitumor function of tumor infiltrated CAR-T cells could be rescued upon interference of the adenosine pathway using A2a receptor small molecule inhibitors. This study signifies the effects adenosine has on tumor infiltrating immune cells and demonstrated a strategy in which it could be overcome, in order to improve the efficacy of CAR-T cell therapy. The second obstacle we aim to overcome is the PD-1/PD-L1 immune regulatory pathway. In the second study, we engineered CAR-T cells to secrete the PD-1/PD-L1 checkpoint inhibitor and evaluated the antitumor efficacy in vivo. This strategy was proved to significantly enhance CAR-T cell effector functions in vivo and was able to completely eradicate established tumors. We evaluated the effector functions in an ex vivo assay and demonstrated that the intrinsically secreted PD-1/PD-L1 checkpoint inhibitor was able to prevent CAR-T cell exhaustion and maintained IFN? secretion upon restimulation.
590 $a School code: 0208.
650 4 $a Chemical engineering. $3 560457
690 $a 0542
710 2 $a University of Southern California. $3 700129
773 0 $t Dissertations Abstracts International $g 80-08B.
790 $a 0208
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=11017006